National Institute of Allergy and Infectious Diseases, Rocky Mountain Labs, Hamilton, MT

A postdoctoral IRTA position on the molecular pathogenesis of emerging viruses is available in the Immunobiology & Molecular Virology Unit within the Laboratory of Virology at the RML campus of NIAID in Hamilton, Montana. The laboratory studies high- and maximum-containment RNA viruses that cause severe hemorrhagic disease with a focus on filoviruses.

The Immunobiology & Molecular Virology Unit) is interested in the pathogenesis of emerging viruses with a focus on filoviruses on every level from host to molecule. The laboratory uses experimental approaches to increase our understanding of the disease induced by these viruses and applies the gained insights to design next-generation countermeasures. Fundamental experimental approaches of the laboratory include molecular and cell-based techniques including viral reverse genetics systems and a variety of animal models. Studies are carried out in biosafety level (BSL)-2 and BSL-4 laboratories. The Immunobiology & Molecular Virology Unit considers diversity and inclusion the centerpiece of the team’s culture.

Successful applicants will be part of a diverse and multidisciplinary team focused on experimental approaches to relevant questions in the pathogenesis and countermeasure development of emerging viruses. The project will focus on molecular mechanisms underlying filovirus pathogenesis. It will rely on the use of viral reverse genetics systems and phenotypical assessment of recombinant viruses in cell culture systems and animal models.

Here is an overview of the Immunobiology & Molecular Virology Unit’s most recent research with regards to pathogenesis and countermeasures for emerging viruses:

• Marzi et al. Species-specific immunogenicity and protective efficacy of a VSV-based Sudan virus vaccine: a challenge study in macaques. The Lancet Microbe 2023
• O’Donnell et al. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. EBioMedicine 2021
• Furuyama et al. The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway. Plos Pathogens 2021

• Highly motivated candidates who have a strong background in virology, molecular biology, computational biology, and immunology are encouraged to apply.
• Experience working in high-containment virology and experience working with reverse genetics systems and animal models would be considered an advantage.
• Well-developed oral and written communication skills are essential.
• Candidates must hold a Ph.D. in virology, molecular biology, or another appropriate discipline and have less than three years of postdoctoral experience.
• Applicants may be U.S. citizens, permanent residents, or international citizens (for an IRTA, visa requirements apply).

Trainees will receive health insurance as well as a stipend commensurate with experience starting at $64,000 per year.

Applicants should send their curriculum vitae (CV), a letter expressing career goals and interests, and three letters of reference with contact information no later than April 30, 2023, to Kay Menk, Laboratory Operations Specialist, Laboratory of Virology, Rocky Mountain Laboratories, NIAID, NIH, 903 S 4th Street, Hamilton, MT 59840, 406-375-9624 (phone), 406-375-9620 (fax), or menkk@niaid.nih.gov .

RML is an NIAID campus with excellent flow cytometry, genomic, cryo-electron microscopy (EM) and high-resolution transmission EM (TEM), and veterinary core support that enables scientists to completely focus on their research. Located in the scenic Bitterroot valley of western Montana, RML is surrounded by some of the best hiking, skiing, kayaking, mountain biking, and trout fishing in North America.

Visit NIAID Careers for more information about working in NIAID’s dynamic atmosphere.

HHS, NIH, and NIAID are equal opportunity employers dedicated to equity, diversity, and inclusion.